We are live on ! Find out more
OMIC

Singular Genomics Systems, Inc. Common Stock
OMIC

Delisted

OMIC was delisted on the 20th of February, 2025.

Back to rankings

62 hedge funds and large institutions have $450M invested in Singular Genomics Systems, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 8 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 8

100% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 10

44% more capital invested

Capital invested by funds: $312M → $450M (+$138M)

19% more funds holding

Funds holding: 52 → 62 (+10)

Holders
62
Holders Change
+10
Holders Change %
+19.23%
% of All Funds
0.95%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
20
Increased
24
Reduced
8
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$16.7M
2
JP Morgan Chase
JP Morgan Chase
New York
+$8.24M
3
BlackRock
BlackRock
New York
+$6.34M
4
PA
Perceptive Advisors
New York
+$3.36M
5
PIM
Platinum Investment Management
Australia
+$2.02M

Top Sellers

Rank Fund Capital Flow
1
CC
Casdin Capital
New York
-$16.2M
2
Marshall Wace
Marshall Wace
United Kingdom
-$5.23M
3
Millennium Management
Millennium Management
New York
-$5.08M
4
JPC
Jabodon PT Co
Nevada
-$1.11M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$891K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
26
Cinctive Capital Management
New York
$824K +$921K +2,377 New
Marshall Wace
27
Marshall Wace
United Kingdom
$780K -$5.23M -13,484 -86%
Bank of America
28
Bank of America
North Carolina
$755K +$788K +2,032 +1,392%
Citadel Advisors
29
Citadel Advisors
Florida
$684K -$296K -763 -28%
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$645K +$298K +770 +71%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$638K +$51.6K +133 +8%
E
32
Ergoteles
New York
$582K +$650K +1,678 New
New York State Common Retirement Fund
33
New York State Common Retirement Fund
New York
$408K +$104K +269 +30%
Citigroup
34
Citigroup
New York
$393K +$422K +1,089 +2,420%
Charles Schwab
35
Charles Schwab
California
$363K +$27.1K +70 +7%
Walleye Capital
36
Walleye Capital
New York
$310K +$346K +892 New
Qube Research & Technologies (QRT)
37
Qube Research & Technologies (QRT)
United Kingdom
$268K +$299K +772 New
Temasek Holdings
38
Temasek Holdings
Singapore
$247K +$277K +714 New
RCG
39
Rock Creek Group
District of Columbia
$207K +$345K +889 New
SO
40
STRS Ohio
Ohio
$202K +$191K +493 +548%
CSS
41
Cubist Systematic Strategies
Connecticut
$191K +$213K +550 New
Morgan Stanley
42
Morgan Stanley
New York
$189K +$140K +361 +194%
Jane Street
43
Jane Street
New York
$187K +$209K +538 New
PPA
44
Parametric Portfolio Associates
Washington
$181K -$285K -735 -58%
TFS
45
TrustCore Financial Services
Tennessee
$177K – – –
N
46
Nuveen
North Carolina
$171K – – –
ProShare Advisors
47
ProShare Advisors
Maryland
$148K +$165K +426 New
AGM
48
Alpine Global Management
New York
$135K +$152K +391 New
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$133K +$148K +383 New
PP
50
Paloma Partners
Connecticut
$116K +$129K +334 New
1
2
3

OMIC Hedge Fund Activity: Q4 2021 in Review

62 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Singular Genomics Systems, Inc. Common Stock (OMIC) for Q4 2021, worth a combined $450M — up 44% from $312M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new OMIC positions and 10 closed out — a net gain of 10 holders — while 24 added to existing stakes and 8 trimmed.

The largest buyer was Vanguard Group, adding an estimated $16.7M. The largest seller was Casdin Capital, cutting an estimated $16.2M.

  • 62 institutional investors held Singular Genomics Systems, Inc. Common Stock (OMIC) as of Q4 2021, up from 52 in Q3 2021.
  • Funds reported $450M of Singular Genomics Systems, Inc. Common Stock stock for Q4 2021, up 44% quarter-over-quarter.
  • 20 funds opened new Singular Genomics Systems, Inc. Common Stock positions in Q4 2021 and 10 closed out, a net change of +10 holders.
  • The largest Singular Genomics Systems, Inc. Common Stock buyer in Q4 2021 was Vanguard Group, an estimated $16.7M added.
  • The largest Singular Genomics Systems, Inc. Common Stock seller in Q4 2021 was Casdin Capital, an estimated $16.2M sold.

Based on aggregated 13F filings for Q4 2021.